JP2024520132A5 - - Google Patents
Info
- Publication number
- JP2024520132A5 JP2024520132A5 JP2023574354A JP2023574354A JP2024520132A5 JP 2024520132 A5 JP2024520132 A5 JP 2024520132A5 JP 2023574354 A JP2023574354 A JP 2023574354A JP 2023574354 A JP2023574354 A JP 2023574354A JP 2024520132 A5 JP2024520132 A5 JP 2024520132A5
- Authority
- JP
- Japan
- Prior art keywords
- line
- inhibitor
- pharmaceutical composition
- composition according
- cognitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163197015P | 2021-06-04 | 2021-06-04 | |
| US63/197,015 | 2021-06-04 | ||
| PCT/US2022/032120 WO2022256625A1 (en) | 2021-06-04 | 2022-06-03 | Line-1 inhibitors as cognitive enhancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520132A JP2024520132A (ja) | 2024-05-21 |
| JP2024520132A5 true JP2024520132A5 (enExample) | 2024-08-05 |
Family
ID=84323626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574354A Pending JP2024520132A (ja) | 2021-06-04 | 2022-06-03 | 向知性薬としてのｌｉｎｅ－１阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240285664A1 (enExample) |
| EP (1) | EP4346835A4 (enExample) |
| JP (1) | JP2024520132A (enExample) |
| KR (1) | KR20240017910A (enExample) |
| CN (1) | CN117813096A (enExample) |
| AU (1) | AU2022283915A1 (enExample) |
| CA (1) | CA3221190A1 (enExample) |
| IL (1) | IL309036A (enExample) |
| MX (1) | MX2023014381A (enExample) |
| WO (1) | WO2022256625A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4358968A4 (en) * | 2021-06-22 | 2025-05-07 | Rome Therapeutics, Inc. | 4-ETHINYL-3-HYDROXY-TETRAHYDROFURANYL ADENINE PHOSPHORAMIDATE AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES |
| EP4482498A4 (en) * | 2022-02-22 | 2026-02-25 | Rome Therapeutics Inc | METHODS OF TREATING MEDICAL PROBLEMS USING CENSAVUDINE OR A COMBINATION COMPOUND |
| US20250186475A1 (en) * | 2022-03-15 | 2025-06-12 | Rome Therapeutics, Inc. | Methods of treating medical conditions using islatravir or a related compound |
| WO2024107850A1 (en) * | 2022-11-15 | 2024-05-23 | Rome Therapeutics, Inc. | Halo-dehydro-3'-deoxyuracil phosphoramidates and related compounds and their use in treating medical conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0104168D0 (en) * | 2001-02-20 | 2001-04-11 | European Molecular Biology Lab Embl | Disease model |
| CA2986891C (en) * | 2015-05-26 | 2022-01-04 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Compositions for use in treating parkinson's disease and related disorders |
| MX2021008751A (es) * | 2019-01-25 | 2021-11-12 | Univ Brown | Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad. |
| US20220160710A1 (en) * | 2019-03-08 | 2022-05-26 | University Of Virginia Patent Foundation | Compositions and methods for treating or preventing alzheimer's disease |
| IL301564A (en) * | 2020-09-23 | 2023-05-01 | Transposon Therapeutics Inc | LINE-1 inhibitors to treat the disease |
-
2022
- 2022-06-03 AU AU2022283915A patent/AU2022283915A1/en active Pending
- 2022-06-03 KR KR1020247000214A patent/KR20240017910A/ko active Pending
- 2022-06-03 MX MX2023014381A patent/MX2023014381A/es unknown
- 2022-06-03 IL IL309036A patent/IL309036A/en unknown
- 2022-06-03 US US18/566,413 patent/US20240285664A1/en active Pending
- 2022-06-03 CN CN202280048917.1A patent/CN117813096A/zh active Pending
- 2022-06-03 CA CA3221190A patent/CA3221190A1/en active Pending
- 2022-06-03 EP EP22816917.3A patent/EP4346835A4/en active Pending
- 2022-06-03 JP JP2023574354A patent/JP2024520132A/ja active Pending
- 2022-06-03 WO PCT/US2022/032120 patent/WO2022256625A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540183A5 (enExample) | ||
| JP2024156774A5 (enExample) | ||
| JP2019059760A5 (enExample) | ||
| JP2022191257A5 (enExample) | ||
| JP2022537047A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2020519661A5 (enExample) | ||
| RU2006109491A (ru) | Новые трициклические нуклеозиды или нуклеотиды в качестве терапевтических средств | |
| JP2023166406A5 (enExample) | ||
| JP2022539185A5 (enExample) | ||
| JP2010532373A5 (enExample) | ||
| EA200602130A1 (ru) | Замещенные арилацилтиомочевины и родственные соединения; ингибиторы репликации вирусов | |
| JP2020507589A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| JPWO2023054732A5 (enExample) | ||
| JP2022533968A5 (enExample) | ||
| JP2023546565A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| JP2022531251A5 (enExample) | ||
| JP2022545156A5 (enExample) | ||
| JP2023531675A5 (enExample) | ||
| CN1750835A (zh) | 治疗疼痛的化合物 | |
| JP2023531930A5 (enExample) | ||
| RU2491931C2 (ru) | Способы лечения тревоги | |
| JP2023521180A5 (enExample) |